Apparent and internal validity of a Monte Carlo-Markov model for cardiovascular disease in a cohort follow-up study

Medical Decision Making

Volumn 26, Issue 2, 2006, Pages 134-144

  Nijhuis, Rogier L ^a   Stijnen, Theo ^a   Peeters, Anna ^a   Witteman, Jacqueline C M ^a   Hofman, Albert ^a   Hunink, M G Myriam ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Apparent and internal; Cardiovascular disease; Cohort follow up study; Monte Carlo Markov model; Validation

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; MONTE CARLO METHOD; PROBABILITY; SIMULATION; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MONTE CARLO METHOD; NETHERLANDS; RISK FACTORS;

EID: 33646720058     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X05284103     Document Type: Article

References (24)

1. Anonymous. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Prev Med. 1986;15:254-73.
2. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-8.
3. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571-6.
4. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-6.
5. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-72.
6. Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ. 1997;314:1666-74.
7. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.
8. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
10. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-22.
11. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD. Validity of prognostic models: when is a model clinically useful? Semin Urol Oncol. 2002;20:96-107.
12. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774-81.
13. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-87.
14. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453-73.
15. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985;5;157-77.
16. Hunink MGM, Glasziou PP, Siegel JE, et al. Decision Making in Health and Medicine: Interpreting Evidence and Values. Cambridge (UK): Cambridge University Press; 2001.
17. Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985;69:1071-7.
18. Sakamoto Y, Ishiguro M, Kitagawa G. Akaike Information Criterion Statistics. Dordrecht (the Netherlands): Kluwer; 1986.
19. Kuntz KM, Goldie SJ. Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias. Med Decis Making. 2002;22:218-27.
20. Bonneux L, Barendregt JJ, Nusselder WJ, der Maas PJ. Preventing fatal diseases increases healthcare costs: cause elimination life table approach. BMJ. 1998;316:26-9.
21. Pollard JH, Valkovics EJ. The Gompertz distribution and its applications. Genus. 1992;48:15-28.
22. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med. 1999;18:2529-45.
23. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health. 1987;77:1417-26.
24. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA. 1997;277:535-42.